Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Ltd (ASX: IMRN) provides investors and industry stakeholders with timely updates through this centralized news resource. Track the Australian biopharmaceutical innovator's progress in developing oral immunotherapies targeting gastrointestinal and immune-mediated disorders.
Access verified announcements covering clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Immuron's hyperimmune bovine colostrum platform, product pipeline advancements, and financial disclosures - all essential for understanding the company's position in the immunotherapy sector.
Key focus areas include Travelan® commercialization efforts, research into non-alcoholic fatty liver disease treatments, and novel applications of polyclonal antibody technology. Bookmark this page for efficient monitoring of Immuron's progress in addressing unmet needs across gastroenterology and immunology markets.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has released its Q3 FY23 Investor Presentation, highlighting significant sales growth. For the two weeks ending April 14, 2023, worldwide sales reached A$320,000, representing 37% of the entire Q3 FY23 total of A$875,000. Year-to-date sales for FY23 until April 14 amounted to A$1,779,000, marking a remarkable 233% increase compared to A$534,000 for the same period in FY22. The company is focusing on its oral immunotherapeutic products for gut-mediated diseases. Investors are invited to participate in a webinar hosted by CEO Steven Lydeamore for further insights.
FAQ
What is the current stock price of Immuron (IMRN)?
What is the market cap of Immuron (IMRN)?
